{"transactions":[{"id":1214640,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Restricted Stock Units","published_at":"2025-03-10T20:12:58.000Z","date":"2025-03-07","kind":"exercise","planned":false,"acquired":false,"shares":11041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Sana common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date."}],"balance_after":33126,"derivative":{"underlying":"Common Stock","underlying_shares":11041},"source":{"system":"sec-edgar","filing":"0001562180-25-002273","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218025002273/primarydocument.xml","form_type":"4"}},{"id":1214639,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T20:12:58.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."}],"balance_after":240000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001562180-25-002273","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218025002273/primarydocument.xml","form_type":"4"}},{"id":1214638,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Restricted Stock Units","published_at":"2025-03-10T20:12:58.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":53333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Sana common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."}],"balance_after":53333,"derivative":{"underlying":"Common Stock","underlying_shares":53333},"source":{"system":"sec-edgar","filing":"0001562180-25-002273","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218025002273/primarydocument.xml","form_type":"4"}},{"id":1214637,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2025-03-10T20:12:58.000Z","date":"2025-03-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2833,"price":2.56,"value":7252.48,"ownership":{"direct":true},"balance_after":112990,"source":{"system":"sec-edgar","filing":"0001562180-25-002273","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218025002273/primarydocument.xml","form_type":"4"}},{"id":1214636,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Common Stock","published_at":"2025-03-10T20:12:58.000Z","date":"2025-03-07","kind":"exercise","planned":false,"acquired":true,"shares":11041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,001 shares acquired on May 15, 2023 and 3,000 shares acquired on each of November 15, 2023, May 15, 2024 and November 15, 2024, in each case, pursuant to Sana Biotechnology, Inc.'s (\"Sana\") 2021 Employee Stock Purchase Plan."}],"balance_after":115823,"source":{"system":"sec-edgar","filing":"0001562180-25-002273","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218025002273/primarydocument.xml","form_type":"4"}},{"id":1586140,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-08T16:16:02.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":198750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."}],"balance_after":198750,"derivative":{"exercise_price":9.58,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":198750},"source":{"system":"sec-edgar","filing":"0001562180-24-002474","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218024002474/primarydocument.xml","form_type":"4"}},{"id":1586139,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Restricted Stock Units","published_at":"2024-03-08T16:16:02.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":44167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (\"Sana\") common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date."}],"balance_after":44167,"derivative":{"underlying":"Common Stock","underlying_shares":44167},"source":{"system":"sec-edgar","filing":"0001562180-24-002474","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218024002474/primarydocument.xml","form_type":"4"}},{"id":1972085,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-03T16:35:27.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter."}],"balance_after":140000,"derivative":{"exercise_price":3.76,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001562180-23-002396","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218023002396/primarydocument.xml","form_type":"4"}},{"id":2157051,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-16T18:52:41.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on September 15, 2023 and in 36 equal monthly installments thereafter."}],"balance_after":800000,"derivative":{"exercise_price":7.13,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001562180-22-006711","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000156218022006711/primarydocument.xml","form_type":"4"}},{"id":4007652,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":113636,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":113636},"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007651,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":24.5,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007650,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":50500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":48.06,"expiration_date":"2025-03-02","underlying":"Common Stock","underlying_shares":50500},"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007649,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":8.72,"expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007648,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007647,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"other","acquired":false,"shares":26869,"price":87,"value":2337603.0,"ownership":{"direct":false,"nature":"By Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F8","text":"Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007646,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":35893,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F6","text":"Represents performance-based restricted stock awards (\"PSAs\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007645,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":25639,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":35893,"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007644,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":18293,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":61532,"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4007643,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-03-07T18:16:02.000Z","date":"2018-03-05","kind":"other","acquired":false,"shares":5558,"price":87,"value":483546.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (4) through (7) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 121 shares acquired under the Company's employee stock purchase plan on February 23, 2018."}],"balance_after":79825,"source":{"system":"sec-edgar","filing":"0001209191-18-017802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118017802/doc4.xml","form_type":"4"}},{"id":4068228,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-02-09T19:31:30.000Z","date":"2018-02-07","kind":"gift","acquired":false,"shares":26634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a bona fide gift of common stock; thus, there is no price associated with this transaction."}],"balance_after":85262,"source":{"system":"sec-edgar","filing":"0001209191-18-009015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118009015/doc4.xml","form_type":"4"}},{"id":4068227,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-02-09T19:31:30.000Z","date":"2018-02-07","kind":"tax_withholding","acquired":false,"shares":1528,"price":85.49,"value":130628.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":111896,"source":{"system":"sec-edgar","filing":"0001209191-18-009015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118009015/doc4.xml","form_type":"4"}},{"id":4078629,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2018-02-02T19:29:47.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":25639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 431 shares acquired under the issuer's employee stock purchase plan on May 15, 2017 and 437 shares acquired under the issuer's employee stock purchase plan on November 15, 2017."}],"balance_after":113424,"source":{"system":"sec-edgar","filing":"0001209191-18-007210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919118007210/doc4.xml","form_type":"4"}},{"id":4182379,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2017-10-20T20:26:14.000Z","date":"2017-10-20","kind":"grant","acquired":true,"shares":35893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards (\"RSAs\") granted pursuant to the 2014 Equity Incentive Plan. The RSAs will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date:\n\nUp to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the \"FDA\") of JCAR017 in any indication within certain designated timeframes (the \"JCAR017 Milestone\"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement.\n\nUp to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes."}],"balance_after":86917,"source":{"system":"sec-edgar","filing":"0001209191-17-057694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919117057694/doc4.xml","form_type":"4"}},{"id":4209073,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2017-09-14T19:33:12.000Z","date":"2017-09-14","kind":"sale","acquired":false,"shares":1505,"price":46.5797,"value":70102.4485,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $46.38 to $46.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":51024,"source":{"system":"sec-edgar","filing":"0001209191-17-052873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919117052873/doc4.xml","form_type":"4"}},{"id":4209072,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2017-09-14T19:33:12.000Z","date":"2017-09-14","kind":"sale","acquired":false,"shares":3441,"price":45.9002,"value":157942.5882,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $45.34 to $46.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":52529,"source":{"system":"sec-edgar","filing":"0001209191-17-052873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919117052873/doc4.xml","form_type":"4"}},{"id":4209071,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2017-09-14T19:33:12.000Z","date":"2017-09-14","kind":"sale","acquired":false,"shares":23054,"price":44.6656,"value":1029720.7424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $44.27 to $45.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":55970,"source":{"system":"sec-edgar","filing":"0001209191-17-052873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919117052873/doc4.xml","form_type":"4"}},{"id":4459209,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-09T19:34:24.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":113636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":113636,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":113636},"source":{"system":"sec-edgar","filing":"0001209191-17-009294","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919117009294/doc4.xml","form_type":"4"}},{"id":4459208,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":82192,"kind":"person","name":"Cassidy Bernard J","position":1,"cik":"0001398322","reported_name":"Cassidy Bernard J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2017-02-09T19:34:24.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":24390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017."}],"balance_after":79024,"source":{"system":"sec-edgar","filing":"0001209191-17-009294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1398322/000120919117009294/doc4.xml","form_type":"4"}}]}